MA48780A - Peptides antagonistes de pac1 - Google Patents

Peptides antagonistes de pac1

Info

Publication number
MA48780A
MA48780A MA048780A MA48780A MA48780A MA 48780 A MA48780 A MA 48780A MA 048780 A MA048780 A MA 048780A MA 48780 A MA48780 A MA 48780A MA 48780 A MA48780 A MA 48780A
Authority
MA
Morocco
Prior art keywords
pac1
antagonists
peptides
peptides antagonists
Prior art date
Application number
MA048780A
Other languages
English (en)
Inventor
Irwin Chen
su Chong
Essa Hu Harrington
Fang-Tsao Hong
Jason C Long
Leslie P Miranda
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48780A publication Critical patent/MA48780A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA048780A 2017-06-02 2018-06-01 Peptides antagonistes de pac1 MA48780A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762514440P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
MA48780A true MA48780A (fr) 2020-04-08

Family

ID=62685214

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048780A MA48780A (fr) 2017-06-02 2018-06-01 Peptides antagonistes de pac1

Country Status (10)

Country Link
US (1) US11643440B2 (fr)
EP (1) EP3630147B1 (fr)
JP (1) JP7195281B2 (fr)
AR (1) AR111842A1 (fr)
AU (1) AU2018275270B2 (fr)
CA (1) CA3065115A1 (fr)
MA (1) MA48780A (fr)
TW (1) TW201920235A (fr)
UY (1) UY37753A (fr)
WO (1) WO2018222991A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7756001B2 (ja) 2019-06-28 2025-10-17 アムジエン・インコーポレーテツド 抗ｃｇｒｐ受容体／抗ｐａｃ１受容体二重特異性抗原結合タンパク質

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
US5397772A (en) 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ（ｒｅｎｉｌｌａ）ルシフェラーゼのクローニング及び発現
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5480864A (en) 1993-08-06 1996-01-02 Shiseido Co., Ltd. Modified maxadilan protein, its preparation and use, and DNA encoding the protein
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
JPH08333392A (ja) * 1995-06-05 1996-12-17 Shiseido Co Ltd 生理活性ポリペプチド類
US6462016B1 (en) * 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5880972A (en) 1996-02-26 1999-03-09 Pharmacopeia, Inc. Method and apparatus for generating and representing combinatorial chemistry libraries
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1064360B1 (fr) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, proteines fluorescentes gfp, leurs acides nucleiques, et leur utilisation en diagnostic
US20020182729A1 (en) * 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
WO2003009817A2 (fr) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
WO2003092716A2 (fr) 2002-05-03 2003-11-13 Neuronova Ab Role fonctionnel et utilisation therapeutique potentielle de pacap, vip et maxadilan en rapport avec des cellules progenitrices ou souches neuronales chez l'adulte
JP2006516187A (ja) 2002-10-29 2006-06-29 アメリカ合衆国 ルツォーミアロンギパルピスポリペプチドおよび使用方法
CN101125881A (zh) * 2007-07-20 2008-02-20 暨南大学 重组pac1受体结抗剂d(25-44)rmmax及其表达方法与应用
WO2009033489A2 (fr) * 2007-09-11 2009-03-19 Glostrup Hospital Traitement de la migraine et de céphalées par des inhibiteurs sélectifs de pac1
CN102066411A (zh) 2008-05-08 2011-05-18 梅里亚有限公司 使用白蛉唾液免疫原的利什曼原虫疫苗
EP2313783A2 (fr) 2008-07-18 2011-04-27 Galderma Research & Development Modulateurs de voie de signalisation pacap pour traiter des maladies inflammatoires de la peau avec une composante neurogène et plus particulièrement l acné rosacée et composition contenant ceux-ci
WO2010078469A2 (fr) 2008-12-31 2010-07-08 The Usa As Represented By The Secretary, Department Of Health And Human Services Protéines salivaires de phlébotome en tant que nouveaux inhibiteurs du facteur xa et procédés d'utilisation
JP5447784B2 (ja) 2009-03-12 2014-03-19 国立大学法人 鹿児島大学 マキサディランの部分ペプチドを含む神経因性疼痛の治療剤
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same

Also Published As

Publication number Publication date
AU2018275270B2 (en) 2024-06-06
AU2018275270A1 (en) 2019-12-12
AR111842A1 (es) 2019-08-21
UY37753A (es) 2018-11-30
US20210395313A1 (en) 2021-12-23
WO2018222991A2 (fr) 2018-12-06
JP7195281B2 (ja) 2022-12-23
CA3065115A1 (fr) 2018-12-06
EP3630147B1 (fr) 2026-03-25
US11643440B2 (en) 2023-05-09
TW201920235A (zh) 2019-06-01
JP2020522476A (ja) 2020-07-30
EP3630147A2 (fr) 2020-04-08
WO2018222991A3 (fr) 2019-01-31

Similar Documents

Publication Publication Date Title
IL268920A (en) Peptide vaccines
DK3727461T3 (da) EPHA2-specifikke bicykliske peptidligander
IL268593A (en) Polypeptide variants and uses thereof
DK3723783T3 (da) Mitokondrie-målrettede peptider
PL3649151T3 (pl) Białka rusztowania
EP3362556C0 (fr) Variants polypeptidiques
EP3317294A4 (fr) Peptides stabilisés anti-microbiens
IL254516A0 (en) Proteins specific for cd137
GB201706477D0 (en) Modification of polypeptides
LT3143037T (lt) Alfa4beta7 integrino tioeterio peptidų antagonistaii
DK4089113T3 (da) Polypeptider
LT3298027T (lt) Antihelmintiniai depsipeptido junginiai
PT3645518T (pt) Síntese de omecamtiv mecarbil
IL254591A0 (en) Polypeptides
DK3259358T3 (da) Forøget proteinekspression
EP3710462A4 (fr) Analogues de brartémicine
DK3448879T3 (da) Claudin-6 peptider
EP3733686A4 (fr) Nouveau peptide
EP3684359C0 (fr) Antagonistes de trpv2
SE1830065A1 (sv) Spherical beraring
EP3703716A4 (fr) Expression de neuropeptides
EP3720873C0 (fr) Peptides de type glucagon
EP3647426A4 (fr) Protéine de fusion
EP3967705C0 (fr) Peptides dérivés de glycoprotéines du virus rabique (rvg)
EP3424943A4 (fr) Peptide